CMBA
BTAI icon

C.M. Bidwell & Associates’s BioXcel Therapeutics BTAI Stock Holding History

C.M. Bidwell & Associates’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-156
Closed -$19K – 397
2018
Q3 		$19K Hold
156
– – 0.02% 285
2018
Q2 		$23K Buy
+156
New +$23.8K 0.02% 289

Other funds holding BTAI

AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

C.M. Bidwell & Associates's BTAI Position: Q4 2018 in Review

C.M. Bidwell & Associates sold out of BioXcel Therapeutics (BTAI) in Q4 2018, closing a stake of 156 shares — an estimated $19K sold.

C.M. Bidwell & Associates first reported a position in BTAI in Q2 2018 and held it in 2 quarters. The position peaked at $23K in Q2 2018. 11 funds tracked by Wall St. Rank hold BTAI as of Q4 2018.

  • C.M. Bidwell & Associates reported no remaining BioXcel Therapeutics position as of Q4 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 156 BioXcel Therapeutics shares in Q4 2018, an estimated $19K.
  • C.M. Bidwell & Associates first reported a position in BioXcel Therapeutics in Q2 2018 and held it in 2 quarters.
  • C.M. Bidwell & Associates's BioXcel Therapeutics position peaked at $23K in Q2 2018.
  • 11 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.